Page 25 - Arix Bioscience News Today

Deal expands anti-infectives pipeline with addition of novel antifungal Phase 2 candidate, Fosmanogepix Opportunity to advance Pfizer’s expertise and deep heritage in infectious disease ... | April 28, 2021

Opportunity to advance Pfizer’s expertise and deep heritage in infectious disease NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasiv...

About Arix Bioscience plc Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.   We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. ww...

Arix Biosciences portfolio firm Amplyx snapped up by Pfizer Amplyx, which develops therapies for debilitating and life-threatening diseases that affect people with compromised immune systems, will be acquired by Pfizer following an initial investment from the pharma giant in 2019 Arix Bioscience PLC (LON:ARIX) said one of its portfolio companies, Amplyx Pharmaceuticals, is to be acquired by US pharma giant Pfizer Inc (NYSE:PFE) in a deal it said will result in a small increase to its holding in...

LogicBio announces clinical and corporate updates DJ LogicBio announces clinical and corporate updates Arix Bioscience PLC (ARIX) LogicBio announces clinical and corporate updates 27-Apr-2021 / 14:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. =---------------------------------------------------------------------------------------------------------------------- Arix Bioscience plc Log...

EXECUTIVE CHANGES: Ebiquity appoints ITV executive Izlan to board Mon, 26th Apr 2021 16:02 (Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and not separately reported by Alliance News: Ebiquity PLC - marketing and media consultancy - Appoints Lara Izlan as non-executive director with effect on June 1. Is currently director of Data Strategy at FTSE-250 listed broadcaster ITV PLC. Arix Bioscience PLC - firm which invests in b...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

Arix Bioscience PLC: Transaction in own shares DJ Transaction in own shares Arix Bioscience PLC (ARIX) Transaction in own shares 19-Apr-2021 / 17:09 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. =---------------------------------------------------------------------------------------------------------------------- Arix Bioscience plc Transaction in own shares LONDON, 19 April 2021: Arix...

DJ Transaction in own shares Arix Bioscience PLC (ARIX) Transaction in own shares 12-Apr-2021 / 17:22 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is

Shareholder broadside at biotech investor Arix’s board 10 April 2021 • 8:20pm Acacia Research last year bought the 19pc stake in Arix Bioscience that was previously owned by Neil Woodfords fund Credit: Geoff Pugh Arix Bioscience, the biotechnology investor backed by restaurant tycoon Richard Caring and biotech entrepreneur Sir Christopher Evans, has been forced to halt two board appointments after its largest shareholder called for a total overhaul in a scathing letter. Mayfair-based Arix h...